Clinical trials: Kidney Function
Renal Impairment, Gout
Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients
Our findings are expected to provide real-world evidence of the renal-adverse effects of colchicine and NSAIDs combination therapy in patients with gout, which will guide healthcare professions in optimizing gout treatment…
- Conditions
- Renal Impairment, Gout, Colchicine Adverse Reaction, Nonsteroidals (NSAIDs)Toxicity
- Trial name
- NCT05006001
- Testing
- Colchicine and NSAID
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- En Chu Kong Hospital
COVID 19
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent…
- Trial name
- NCT06698549
- Testing
- ALG-097558
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Chronic Kidney Diseases
DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
This is a feasibility study to assess new, more practical ways of measuring renal reserve.
- Trial name
- DYNAMO (NCT06572215)
- Testing
- Dapagliflozin
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Myelofibrosis
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with renal impairment after a single dose, and to evaluate the urinary…
- Trial name
- NCT06598956
- Testing
- TQ05105
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Impairment, Healthy Participants
Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired renal function compared to matched control subjects with normal renal function
- Trial name
- NCT03961932
- Testing
- Linzagolix
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- ObsEva SA
Healthy, Renal Impairment
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects.
- Trial name
- NCT01761773
- Testing
- cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Exelixis
Fabry Disease
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects…
- Trial name
- NCT01730469
- Testing
- AT1001 150 mg
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Chronic Kidney Diseases
LONGitudinal Multi-omics Phenotyping of KIDney Function Alteration
This is a longitudinal observation of kidney function, immune system and gut microbiota before and 24 weeks after a live kidney transplantation conducted in donor and recipient pairs living in the same household.
- Trial name
- NCT05570929
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Insomnia
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
This study will investigate whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with impaired renal function are similar to those observed in healthy participants; and…
- Trial name
- NCT01059851
- Testing
- Suvorexant
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Diabetes Mellitus, Type 2
School-Based Program On Metabolic Disease
Mexico occupies the first place worldwide in childhood obesity. Its urban and indigenous communities present different levels of westernization which have triggered different epidemiological diseases.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Cardiovascular Function, Kidney Diseases
- Trial name
- NCT03768245
- Testing
- Health Education and Physical activity program, Nutrition Program
- Where
- Mexico
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Estimated Creatinine Clearance
Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese
It's important to dose according to renal function in who has impaired kidney function. There are two common methods estimating renal function: one is creatinine clearance estimated by Cockcroft-Gault (CG) equation; another is…
- Trial name
- NCT02040181
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Diet, Healthy
Investigate Beneficial Effect of Herbal Tea in Jordanian Adults
investigate beneficial effect of an herbal tea prepared from carob pulp and pods (Ceratonia siliqua), anise seed (Pimpinella Anisum L), wild thyme, green tea and eucalyptus leaves with Manuka honey (natural sweetener) on lipid…
- Trial name
- herbaltea (NCT04093128)
- Testing
- herbal tea intervention
- Where
- Jordan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dr.Ruba Musharbash
Kidney Functional
GLP-1: Acute Effects on Kidney Function in Healthy Men
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.
- Trial name
- NCT01333163
- Testing
- Human GLP-1 (7-36) amide, Isotone NaCl
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jeppe Skov
Kidney Failure, Chronic, Renal Insufficiency, Chronic
A Study of LY2409021 in Participants With Different Levels of Kidney Function
The purpose of this study was to measure how much of the study drug, LY2409021, gets into the blood stream and how long it takes the body to get rid of it when given to participants with different levels of kidney function.
- Trial name
- NCT01929109
- Testing
- LY2409021
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Renal Impairments, IgA Nephropathy (IgAN)
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous…
- Trial name
- NCT07445906
- Testing
- RG002C0106
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Lactic Acidosis
Remote Ischemic Preconditioning During Cardiopulmonary Bypass
The objective of study is to detect effect of remote ischemic preconditioning on serum lactate levels during and after cardiac surgery with cardiopulmonary bypass in addition to its effect on cardiac and renal clinical outcomes.
- Trial name
- RIPC (NCT03723993)
- Testing
- Inflated cuff, Non inflated cuff
- Where
- Egypt
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fayoum University
Renal Impairment
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of a single dose of inclisiran subcutaneous (SC) injection in participants with mild…
- Trial name
- NCT03159416
- Testing
- Inclisiran
- Where
- 2 sites in New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- The Medicines Company
Cardiovascular Disease
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
The purpose of this study is to measure how much of the study drug, evacetrapib, enters the blood stream and how long it takes the body to dispose of the study drug when given to participants with severe renal (kidney) impairment…
- Trial name
- NCT01825889
- Testing
- Evacetrapib
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth.
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Trial name
- NCT00501462
- Testing
- GSK189075
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline